Literature DB >> 10586998

Performance of compressed analogue (CA) and continuous interleaved sampling (CIS) coding strategies for cochlear implants in quiet and noise.

M Kompis1, M W Vischer, R Häusler.   

Abstract

Speech understanding with compressed analogue (CA) and continuous interleaved sampling (CIS) coding strategies for cochlear implants was compared in quiet and in noise at signal-to-noise ratios (SNRs) of 15, 10 and 5 dB. The speech recognition of three experienced users of the Ineraid cochlear implant (CA coding strategy) was assessed using a set of sentence, vowel and consonant tests. Three weeks after the fitting of a CIS processor, the tests were repeated with the new device. Speech recognition scores for the sentence and consonant tests tended to be higher with the CIS processor in no or little noise, but lower in the test situations with less favourable SNRs, when compared to the CA processor (average score differences for the consonant test: +7.8% correct at 15 dB SNR; -6.8% correct at 5 dB SNR; p = 0.05). Results for the vowel test were slightly lower on average for the CIS processing strategy at all SNRs. A possible explanation for the differences in performance between CIS and CA in the consonant and sentence tests at different SNRs is the generally higher free-field threshold associated with the CA coding strategy, which may act as a single-channel noise suppression.

Mesh:

Year:  1999        PMID: 10586998     DOI: 10.1080/00016489950180595

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  [Influence of "novel" speech processors on the speech perception performance of cochlear implant users].

Authors:  I Baljić
Journal:  HNO       Date:  2009-06       Impact factor: 1.284

2.  A daily alternating method for comparing different signal-processing strategies in hearing aids and in cochlear implants.

Authors:  Richard S Tyler; Shelley A Witt; Camille C Dunn; Ann E Perreau
Journal:  J Am Acad Audiol       Date:  2008-05       Impact factor: 1.664

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.